That phrase "path to market" has always bothered me. The British would never say that because of the NHS. The "market" is something only an American health official would say. In the UK, they might talk about getting Leronlimab to patients or getting it into the hospitals, but they wouldn't say "path to market."

One of my fellow shareholders assured me NP was paraphrasing. I hope that's the case because "path to market" doesn't pass the smell test.

I do worry that folks are expecting too much from the mtgs this week. They're a step in the right direction though so all-good.

- - -

On a related note, it always bothered me when NP would do mainstream interviews -- medicine based -- and he would always refer to Leronlimab as a "product." He should use the word "medicine" or "drug" instead. Semantics matter where any publicity is concerned so hopefully he'll correct that in the future.